What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE?
about
Heart failure with preserved ejection fraction: emerging drug strategiesTargeting heart failure with preserved ejection fraction: current status and future prospectsBreakthrough in heart failure with preserved ejection fraction: are we there yet?Reporting trends of randomised controlled trials in heart failure with preserved ejection fraction: a systematic reviewHeart failure and Alzheimer's diseaseHeart failure with preserved ejection fractionClinical Phenotypes in Heart Failure With Preserved Ejection FractionAssociation between cardiovascular vs. non-cardiovascular co-morbidities and outcomes in heart failure with preserved ejection fraction.Developing therapies for heart failure with preserved ejection fraction: current state and future directionsUpdate on heart failure with preserved ejection fraction.Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trialsCardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study.Long-term survival for patients with acute decompensated heart failure according to ejection fraction findingsNoncardiac comorbidities in heart failure with reduced versus preserved ejection fractionWhich heart failure patients profit from natriuretic peptide guided therapy? A meta-analysis from individual patient data of randomized trials.Copeptin in patients with heart failure and preserved ejection fraction: a report from the prospective KaRen-study.Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response.Heart failure and dementia: survival in relation to types of heart failure and different dementia disorders.Chronic Heart Failure Clinical Practice Guidelines' Class 1-A Pharmacologic Recommendations: Start-to-End Synergistic Drug Therapy?Comparison of medication practices in patients with heart failure and preserved versus those with reduced ejection fraction (from the Cardiovascular Research Network [CVRN]).Heart failure with preserved ejection fraction in African Americans: The ARIC (Atherosclerosis Risk In Communities) studyMagnitude of and Prognostic Factors Associated With 1-Year Mortality After Hospital Discharge for Acute Decompensated Heart Failure Based on Ejection Fraction FindingsZooming in on the Microvasculature in Heart Failure With Preserved Ejection Fraction.Heart failure with preserved ejection fraction in the elderly: scope of the problem.How do patients with heart failure with preserved ejection fraction die?Biomarkers of diastolic dysfunction and myocardial fibrosis: application to heart failure with a preserved ejection fraction.Pathophysiology of diastolic dysfunction in chronic heart failure.What to do about primary-prevention implantable cardiac defibrillators in patients with improved ejection fraction.Heart failure with preserved ejection fraction: a clinical dilemma.Heart failure with preserved ejection fraction: uncertainties and dilemmas.The clinical dilemma of heart failure with preserved ejection fraction: an update on pathophysiology and management for physicians.How to Develop and Implement a Specialized Heart Failure with Preserved Ejection Fraction Clinical Program.Heart Failure Stages Among Older Adults in the Community: The Atherosclerosis Risk in Communities Study.Rationale and design of the PREFERS (Preserved and Reduced Ejection Fraction Epidemiological Regional Study) Stockholm heart failure study: an epidemiological regional study in Stockholm county of 2.1 million inhabitants.Common atrium: a rare cause of acute decompensated heart failure.Congestive Heart Failure With Apparently Preserved Left Ventricular Systolic Function: A 10-Year Observational Study.Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure.Evaluation of the role of left atrial strain using two-dimensional speckle tracking echocardiography in patients with diabetes mellitus and heart failure with preserved left ventricular ejection fraction.Heart Failure in Patients with Preserved Ejection Fraction: Questions Concerning Clinical Progression.Resting and exercise haemodynamics in relation to six-minute walk test in patients with heart failure and preserved ejection fraction.
P2860
Q24595118-EE4B3862-6A31-4887-87C3-09916B42794AQ26752956-55B8B6E0-7EE8-4030-8268-C9B143140C35Q26771999-5D8CEAEE-CF19-4564-AB1E-78557FCA1151Q26779538-F3B26EF0-1C25-45EA-88BA-94D45BD07B91Q26852526-946091BF-666D-4B82-BA0D-AB3A24805A69Q27024008-14EC9DEE-9C75-434A-AD2D-FA17E74AE419Q28073079-88EE29E4-ECA1-4A2F-82E9-1709E803C47DQ33164540-3956DD7D-9806-4266-B9F5-4A0F66A674F1Q33639223-7453D8D6-5595-4695-B209-4915E0E7F041Q33640339-6E34AD07-A290-4FAB-A15A-571209E66448Q33768602-67C8E28E-BD17-4972-B50A-CD4238BE4E82Q34046332-D4DC82BC-29B2-46A8-9B54-CA71F5FDA3FCQ34173702-26D14938-CEE8-4FCA-8ED2-06C7C487F186Q34625223-BC125295-AEE6-4429-A99C-E197F79883A8Q35792547-62D164E1-8274-47BB-9F83-5D82BCCD5073Q36258899-2F726BEF-22E8-4194-A6D4-E2FC48E4C6ACQ36303452-6525B7FA-AB3E-4478-8FF5-CF3140D497CBQ36361518-E3BAF57B-45EB-47F0-ACD1-9A2BAB56E897Q36661094-216CE3FE-83E7-48E4-96F5-568B34FDE7FEQ36807898-05B7866E-54BD-4A04-9D97-BAC0D29DE055Q36833984-34CC669B-9788-48F1-BEA1-87B2C2F6AD0EQ36836423-0ADBEC4A-F808-4A47-80F9-C6586771B558Q37350630-61D36975-7AEE-4C47-8AB3-FE4153F635EBQ37633991-F62CC465-02D8-4CDF-BCC7-7500133D0F3EQ38101027-8A28B943-6FDA-4828-8C50-765CB151F713Q38110226-CD44145E-4CC7-4DAB-9C3C-98C8D0B414DCQ38135894-81AAFB0F-8DA2-414E-81A4-A987C4C925BBQ38185562-54FDF0D9-83A9-4B29-A61C-346EC77E9E2FQ38195149-B963179D-ACA4-4B75-9E3A-A32050813AF0Q38529003-5EAEDFCC-DEA7-4874-BDE1-4F3DF52BE93EQ38768799-F45FD37B-BC59-496F-9683-6BF65C49F83CQ38802217-CC672641-BC48-4384-9E6F-A1A566432960Q39157911-DF05CE5A-135B-47C9-B34D-AC754E17B12BQ39626663-A0F52B3F-6400-4323-A429-86FEDD7790E8Q41913035-E6C8ABB6-904A-40B6-85D4-DA263F67A247Q46610908-C06DD9BC-0F16-46BF-8F25-088E6BC475FBQ47386435-E89FFAD5-CAF5-44DE-A2A0-E7E0EB9A613FQ48606556-396B8571-2833-458F-840D-46F121D590BBQ49204428-1001AB8A-5F61-4598-B067-0673771425B0Q49832176-009185AF-9761-4B9D-8E38-FEA2FC645442
P2860
What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE?
description
2012 nî lūn-bûn
@nan
2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
What have we learned about pat ...... ARM-preserved, and I-PRESERVE?
@ast
What have we learned about pat ...... ARM-preserved, and I-PRESERVE?
@en
What have we learned about pat ...... ARM-preserved, and I-PRESERVE?
@nl
type
label
What have we learned about pat ...... ARM-preserved, and I-PRESERVE?
@ast
What have we learned about pat ...... ARM-preserved, and I-PRESERVE?
@en
What have we learned about pat ...... ARM-preserved, and I-PRESERVE?
@nl
prefLabel
What have we learned about pat ...... ARM-preserved, and I-PRESERVE?
@ast
What have we learned about pat ...... ARM-preserved, and I-PRESERVE?
@en
What have we learned about pat ...... ARM-preserved, and I-PRESERVE?
@nl
P2093
P3181
P1476
What have we learned about pat ...... ARM-preserved, and I-PRESERVE?
@en
P2093
Mark C. Petrie
Nathaniel M. Hawkins
Pardeep S. Jhund
Ross T. Campbell
P304
P3181
P356
10.1016/J.JACC.2012.04.064
P407
P577
2012-12-11T00:00:00Z